Alzheimer's Prevention Trial - Science and Significance

Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history. Richard Schelller, Genentech's Executive Vice President of Research and Early Development, discusses the science behind the trial and it's historic significance.